Sight Sciences Inc
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 13.4% | 14.8% | 14.5% | 14.2% | 16.1% | 13.2% | 13.8% | 15.2% | 13.6% | 12.7% | 13.8% | 8.6% | 12.0% | |
| 86.6% | 85.2% | 85.5% | 85.8% | 83.9% | 86.8% | 86.2% | 84.8% | 86.4% | 87.3% | 86.2% | 91.4% | 88.0% | |
| 21.2% | 18.3% | 24.1% | 20.2% | 23.5% | 22.5% | 25.3% | 22.4% | 16.8% | 12.0% | 12.9% | 10.7% | 13.0% | |
| 132.5% | 115.0% | 137.9% | 124.8% | 116.0% | 119.5% | 140.1% | 122.0% | 109.3% | 93.3% | 136.3% | 97.3% | 108.4% | |
| 153.6% | 144.4% | 161.9% | 145.0% | 139.6% | 149.4% | 165.4% | 144.4% | 126.1% | 105.3% | 149.2% | 108.0% | 121.4% | |
| -67.0% | -59.3% | -76.4% | -59.2% | -55.7% | -62.5% | -79.2% | -59.6% | -39.7% | -18.0% | -63.0% | -16.6% | -33.4% | |
| 7.2% | 7.2% | 6.2% | 5.4% | 5.7% | 6.1% | 7.2% | 6.6% | 6.6% | 6.3% | 6.4% | 5.5% | 6.2% | |
| -64.8% | -57.0% | -84.3% | -57.6% | -54.1% | -61.9% | -80.6% | -60.8% | -41.4% | -20.4% | -65.8% | -18.9% | -35.7% | |
| 0.4% | 0.1% | 0.1% | 0.1% | 0.8% | 0.2% | 0.2% | 0.2% | -0.4% | 0.0% | 0.1% | 0.1% | 0.0% | |
| -65.1% | -57.0% | -84.4% | -57.7% | -54.9% | -62.1% | -80.8% | -61.0% | -41.0% | -20.4% | -65.9% | -19.0% | -35.7% | |
| -56.8% | -48.7% | -77.1% | -51.8% | -47.6% | -54.9% | -72.5% | -53.6% | -34.3% | -13.5% | -58.9% | -19.5% | -30.9% |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: September 23, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.